title: Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?
authors.affiliation: Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, Great Maze Pond, London, UK.
authors.forename: Donal
authors.initials: D
authors.lastname: McLornan
authors.forename: Claire
authors.initials: C
authors.lastname: Harrison
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors / Q000235:genetics; D058990:Molecular Targeted Therapy; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000201:enzymology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D053614:Janus Kinase 2; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human; C507924:JAK2 protein, human